Cargando…

Myositis interstitial lung disease and autoantibodies

The aim of this review is to examine and evaluate published literature associated with idiopathic inflammatory myopathies (IIM) and interstitial lung disease (ILD) based on myositis specific autoantibodies (MSA) and the potential clinical significance of each autoantibody subtype for the practicing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhry, Shire, Christopher-Stine, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296774/ https://www.ncbi.nlm.nih.gov/pubmed/37384043 http://dx.doi.org/10.3389/fmed.2023.1117071

Ejemplares similares

Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis
por: Ceribelli, Angela, et al.
Publicado: (2023)

Significance of Myositis Autoantibody in Patients with Idiopathic Interstitial Lung Disease
por: Song, Ju Sun, et al.
Publicado: (2015)

Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease
por: Mammen, Andrew L., et al.
Publicado: (2015)

Clinical features and outcomes of patients with myositis associated-interstitial lung disease
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
por: Moll, Sofia A., et al.
Publicado: (2020)

Treatment Outcomes of Infectious and Non-infectious Acute Exacerbation of Myositis-Related Interstitial Lung Disease
por: Lee, Hyun, et al.
Publicado: (2022)

The Role of Myositis-Specific Autoantibodies in the Dermatomyositis Spectrum
por: Marasandra Ramesh, Harshita, et al.
Publicado: (2022)

Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
por: Lia, Yihua, et al.
Publicado: (2021)

Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort
por: Chen, Fang, et al.
Publicado: (2022)

“Management of myositis associated interstitial lung disease”
por: Thong, Lorraine, et al.
Publicado: (2023)

Management of Myositis-Associated Interstitial Lung Disease
por: Fujisawa, Tomoyuki
Publicado: (2021)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Prognostic Factors for Myositis-Associated Interstitial Lung Disease
por: Fujisawa, Tomoyuki, et al.
Publicado: (2014)

Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies
por: Ceribelli, Angela, et al.
Publicado: (2020)

Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy
por: Gono, Takahisa, et al.
Publicado: (2022)

Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis
por: Sabbagh, Sara E., et al.
Publicado: (2021)

Myositis autoantibodies and clinical phenotypes
por: Ghirardello, Anna, et al.
Publicado: (2014)

Analysis of myositis autoantibodies in Chinese patients with cancer‐associated myositis
por: Li, Liubing, et al.
Publicado: (2020)

Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis
por: Kang, Eun Ha, et al.
Publicado: (2010)

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer
por: Betteridge, Zoe E., et al.
Publicado: (2018)

Bench to bedside review of myositis autoantibodies
por: Palterer, Boaz, et al.
Publicado: (2018)

Anti Jo-1 myositis. 'Mechanic's hands' and interstitial lung disease.
por: Taggart, A. J., et al.
Publicado: (2002)

Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis
por: Vojinovic, Tamara, et al.
Publicado: (2020)

High-Resolution CT Findings of Myositis-Related Interstitial Lung Disease
por: Egashira, Ryoko
Publicado: (2021)

The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
por: Rider, Lisa G., et al.
Publicado: (2013)

The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis
por: Tansley, Sarah L., et al.
Publicado: (2020)

A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies
por: Sambataro, Gianluca, et al.
Publicado: (2022)

Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
por: Rivière, Amélie, et al.
Publicado: (2022)

Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review
por: Swartzman, Isaac, et al.
Publicado: (2022)

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity
por: Tansley, Sarah L, et al.
Publicado: (2020)

Asymptomatic necrotizing myositis in a young male with progressive interstitial lung disease
por: Baah, Samantha, et al.
Publicado: (2021)

Myositis-Related Interstitial Lung Disease: A Respiratory Physician’s Point of View
por: Waseda, Yuko
Publicado: (2021)

Myositis-specific autoantibodies: detection and clinical associations
por: van Dooren, Sander H. J., et al.
Publicado: (2011)

Clinical Usefulness of Autoantibodies in Idiopathic Inflammatory Myositis
por: García-De La Torre, Ignacio
Publicado: (2015)

Tropomyosin autoantibodies associated with checkpoint inhibitor myositis
por: Zaenker, Pauline, et al.
Publicado: (2020)

Myositis Specific Autoantibodies: A Clinical Perspective
por: Alenzi, Fahidah M
Publicado: (2020)

In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
por: Chinoy, Hector, et al.
Publicado: (2006)

Myositis-specific Antibodies: Overview and Clinical Utilization
por: Halilu, Fatima, et al.
Publicado: (2022)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Assessment of Optimal Screening Tests for the Detection of an Inflammatory Myositis-associated Interstitial Lung Disease
por: Castillo, Sonia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jg88v1vgg5embf8599s37dmg4c